Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johann D Ringe

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Medizinische Klinik (Munich, Germany : 1983)|July 11, 2006
[Drug therapy for prevention of falls and fractures]Johann D Ringe
Medizinische Monatsschrift Fur Pharmazeuten|May 19, 2009
[Combination treatment in osteoporosis. Basic treatment plus specific osteoporosis medication]Johann D Ringe
Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum|April 28, 2012
The effect of Vitamin D on falls and fracturesJohann D Ringe
Patient Preference and Adherence|August 10, 2010
Development of clinical utility of zoledronic acid and patient considerations in the treatment of osteoporosisJohann D Ringe
Rheumatology International|October 19, 2004
Questions on the superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosisJohann D Ringe
MMW Fortschritte Der Medizin|May 29, 2009
[Atrial fibrillation during bisphosphonate therapy. side effects or coincidental finding?]Johann D Ringe
Expert Review of Endocrinology & Metabolism|February 13, 2019
Zoledronic acid in the treatment of Paget's disease and other benign bone disordersJohann D Ringe
Rheumatology International|September 10, 2010
Alfacalcidol improves muscle power, muscle function and balance in elderly patients with reduced bone massE Schacht, Johann D Ringe
Arzneimittel-Forschung|March 2, 2011
Risk reduction of falls and fractures, reduction of back pain and safety in elderly high risk patients receiving combined therapy with alfacalcidol and alendronate: a prospective studyErich Schacht, Johann D Ringe
Rheumatology International|May 12, 2009
Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysisJohann D Ringe, Gerd Möller
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Medizinische Klinik (Munich, Germany : 1983)|July 11, 2006
[Drug therapy for prevention of falls and fractures]Johann D Ringe
Medizinische Monatsschrift Fur Pharmazeuten|May 19, 2009
[Combination treatment in osteoporosis. Basic treatment plus specific osteoporosis medication]Johann D Ringe
Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum|April 28, 2012
The effect of Vitamin D on falls and fracturesJohann D Ringe
Patient Preference and Adherence|August 10, 2010
Development of clinical utility of zoledronic acid and patient considerations in the treatment of osteoporosisJohann D Ringe
Rheumatology International|October 19, 2004
Questions on the superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosisJohann D Ringe
MMW Fortschritte Der Medizin|May 29, 2009
[Atrial fibrillation during bisphosphonate therapy. side effects or coincidental finding?]Johann D Ringe
Expert Review of Endocrinology & Metabolism|February 13, 2019
Zoledronic acid in the treatment of Paget's disease and other benign bone disordersJohann D Ringe
Rheumatology International|September 10, 2010
Alfacalcidol improves muscle power, muscle function and balance in elderly patients with reduced bone massE Schacht, Johann D Ringe
Arzneimittel-Forschung|March 2, 2011
Risk reduction of falls and fractures, reduction of back pain and safety in elderly high risk patients receiving combined therapy with alfacalcidol and alendronate: a prospective studyErich Schacht, Johann D Ringe
Rheumatology International|May 12, 2009
Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysisJohann D Ringe, Gerd Möller
Pageof 4